🔥 Featured Questions
🔥 Trending:🆕 NewestBooksEntertainmentSportsRelationshipsBeauty & Skincare
🗂️ Categories:EntertainmentBooksBeauty & SkincareFood & DrinkTech & AIRelationshipsLifestyle & TrendsMoney & FinanceSports
Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?

On August 19, 2026, Moderna shares skyrocketed as much as 177% intraday -- the biggest single-day move in company history -- after Moderna and Merck released 5-year Phase 3 data showing their personalized mRNA cancer vaccine, combined with Keytruda, sustained a meaningful reduction in melanoma recurrence. The rally came just two weeks after the FDA approved mFlusiva, Moderna's first mRNA-based flu vaccine for adults 50+, the first mRNA flu shot ever authorized in the US. Because Moderna was heavily shorted going into the announcement, the surge reportedly inflicted roughly $5.5 billion in one-day losses on short sellers, fueling debate over how much of the move is short covering versus a genuine re-rating of the company's pipeline. Reaction has split Wall Street, with some newly bullish on Moderna's expanding mRNA platform, while others warn the stock's valuation has run well ahead of its shrinking COVID/RSV vaccine revenue base.

🗳️ 16 votes so far🏆 Leading: The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base (44%)🥈 This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales (38%)🥉 The cancer vaccine data is a legitimate scientific breakthrough -- a personalized mRNA shot that meaningfully delays melanoma recurrence changes the long-term story for Moderna (19%)🌍 🇨🇳 China
The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base
This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales
The cancer vaccine data is a legitimate scientific breakthrough -- a personalized mRNA shot that meaningfully delays melanoma recurrence changes the long-term story for Moderna

Poll as Guest Infographics
Also worth a voteModerna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?Apple's First Foldable iPhone: Genuine Leap Forward, Overpriced Catch-Up, or a Crease Waiting to Happen?
From around the web

Similar to hewsay's "Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?"

Quoted & linked with attribution — not a hewsay user post.
Institutions are buying Moderna stock : r/ModernaStock. Skip to main contentInstitutions are buying Moderna stock : r/ModernaStock. Open menu Open navigationGo to Reddit Home. Institutions are buying Moderna stock. Institution investors are holding more than 75% of Moderna sha...
reddit.com · Reddit
View original
Title: What indicators show a high potential for a short squeeze in a stock? - Quora What indicators show a high potential for a short squeeze in a stock? Key indicators that a stock is poised for a short squeeze fall into three categories: short-interest metrics, market liqui...
quora.com · Quora
View original
Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?

On August 19, 2026, Moderna's shares skyrocketed as much as 177% in a single session -- the biggest one-day gain in the company's history -- after it and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, hit its primary and secondary endpoints in combination with Keytruda in a Phase 3 melanoma trial of over 1,100 patients. The move added roughly $44 billion in market value in hours and instantly vaulted Moderna past every Wall Street analyst's price target, since the stock had carried only a consensus "Hold" rating and a $52.95 average target just the day before. Short sellers, caught badly offside, are estimated to have lost around $5.5 billion in the squeeze. Is this a legitimate re-rating of a real oncology breakthrough, an overexcited bet on a speculative pipeline still years from approval, or a technically-driven overreaction fueled by short covering that could partially unwind?

🗳️ 17 votes so far🏆 Leading: It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight. (41%)🥈 It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype. (35%)🥉 It's an overreaction -- a short-squeeze, not a rational re-rating. Even after nearly tripling, Moderna's stock remains roughly 67% below its August 2021 peak, and its core COVID vaccine business had been shrinking for years -- one successful trial doesn't erase that structural decline overnight. Trading volume spiked to about 1,819% above average and short sellers reportedly lost $5.5 billion in the move, hallmarks of a technically-driven squeeze where forced short covering, not careful valuation, drove the size and speed of the spike. (24%)🌍 🇨🇳 China, 🇦🇴 Angola
It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.
It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype.
It's an overreaction -- a short-squeeze, not a rational re-rating. Even after nearly tripling, Moderna's stock remains roughly 67% below its August 2021 peak, and its core COVID vaccine business had been shrinking for years -- one successful trial doesn't erase that structural decline overnight. Trading volume spiked to about 1,819% above average and short sellers reportedly lost $5.5 billion in the move, hallmarks of a technically-driven squeeze where forced short covering, not careful valuation, drove the size and speed of the spike.

Poll as Guest Infographics
Also worth a voteModerna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?A 1964 Shelby Cobra Daytona Coupe Just Sold for $42.9 Million, Smashing the American Car Record — Historic Bargain or Sign of a Wildly Overheated Market?The $13.9 Million F.P. Journe Résonance: Proof Independent Watchmaking Has Conquered Horology, or a Speculative Bubble in the Making?
From around the web

Similar to hewsay's "Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?"

Quoted & linked with attribution — not a hewsay user post.
# AI is curing cancer (Moderna's Intismeran vaccine). It doesn't seem like the connection between AI and Moderna and Merck's breakthrough with its skin cancer vaccine, Intismeran, has been made. Moderna stock (MRNA) has gone up 83% year to date on the news that the vaccine is ...
reddit.com · Reddit
View original
# I Just Bought $510K Worth of Moderna Stock. r/ModernaStock - I Just Bought $510K Worth of Moderna Stock. Moderna (MRNA) is completely undervalued right now. It's clear that short sellers are driving down the price in the short term, but in the mid-to-long term, I believe the...
reddit.com · Reddit
View original